This disclosure relates to uses of deoxycholic acid, salts, or derivatives thereof in managing bacterial infections and compositions related thereto. In certain embodiments, this disclosure relates to methods of treating or preventing a bacterial infection comprising administering an effective amount of a deoxycholic acid, salts, or derivatives thereof to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating or preventing Streptococcus pneumoniae comprising administering an effective amount of a deoxycholic acid salt to a subject in need thereof.

This disclosure relates to uses of deoxycholic acid, salts, or derivatives thereof in managing bacterial infections and compositions related thereto. In certain embodiments, this disclosure relates to methods of treating or preventing a bacterial infection comprising administering an effective amount of a deoxycholic acid, salts, or derivatives thereof to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating or preventing Streptococcus pneumoniae comprising administering an effective amount of a deoxycholic acid salt to a subject in need thereof.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.

The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.

Disclosed herein is a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. Also disclosed herein are the uses of the hyaluronan conjugate in treating or preventing neurodegenerative diseases.

Disclosed herein is a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. Also disclosed herein are the uses of the hyaluronan conjugate in treating or preventing neurodegenerative diseases.

Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.